<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00728715</url>
  </required_header>
  <id_info>
    <org_study_id>HGR-0000013</org_study_id>
    <nct_id>NCT00728715</nct_id>
  </id_info>
  <brief_title>Efficacy of Budesonide-Formoterol in Bronchiectasis</brief_title>
  <official_title>Clinical Efficacy and Safety of Budesonide and Formoterol in the Management of Non-Cystic Fibrosis Bronchiectasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Requena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Esteve Labs (Grant)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General de Requena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some studies have concluded that high-dose inhaled steroids (IS) are effective in the
      clinical control of patients with bronchiectasis, however the high doses needed provokes some
      adverse effects and lower doses are not effective. Combined treatment with budesonide and
      formoterol have demostrated to be effective in patients with asthma and COPD achieving the
      reduction of steroid dose thanks to the adition of a long-acting beta 2 agonists. There are
      no studies in the literature analysing the effect of combined treatment in patients with
      bronchiectasis. The objective of this study is to compare the efficacy and safety of
      formoterol-medium dose of budesonide in a single inhaler versus high-dose of budesonide in
      the clinical control of patientes with non-cystic fibrosis bronchiectasis.

      Study Design:

      Randomized (3 months) parallel groups study.

      Patients:

      Patients with bronchiectasis diagnosed by high-resolution CT scan and chronic obstructive
      airway obstruction.

      Exclusion:

      Asthma and current or past smokers.

      Methods:

      Run in period in all patients with high dose of budesonide (1600 mcg/day) for 3 months. After
      that, randomization into two groups: 1. The same treatment (1600 mcg/day of budesonide) or
      combined treatment with lower dose of budesonide (18 mcg/day of formoterol and 800 mcg of
      budesonide) in a single turbuhaler inhaler during 3 months.

      Studied variables:

      Clinical, functional, quality of life, microbiological and number of side effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Health related quality of life (measured by St Gorge Respiratory Questionnaire)</measure>
    <time_frame>at 3 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced spirometry; microbiological data, clinical data (dyspnea, cough, wheezes) and side effects</measure>
    <time_frame>at 3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium Dose of budesonide-formoterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose of inhaled budesonide (1600 mcg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide-formoterol single inhaler</intervention_name>
    <description>High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>B. High-dose budesonide arm</other_name>
    <other_name>A. Medium dose of budesonide plus formoterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose of budesonide</intervention_name>
    <description>1600 mcg/d of budesonide</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A</intervention_name>
    <description>medium dose of budesonide-formoterol</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B</intervention_name>
    <description>High Dose Inhaled Budesonide</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years old patients diagnosed of non-cystic fibrosis bronchiectasis

          -  More than 1 pulmonary lobe affected

          -  Chronic obstructive airflow obstruction

          -  Stable phase of the disease

        Exclusion Criteria:

          -  Asthma, COPD or current/past smnokers

          -  No consent

          -  Known intolerance to budesonide or formoterol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital General de Requena</name>
      <address>
        <city>Valencia</city>
        <zip>43260</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>July 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2008</study_first_posted>
  <last_update_submitted>July 31, 2008</last_update_submitted>
  <last_update_submitted_qc>July 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Miguel Angel Mart√≠nez-Garcia</name_title>
    <organization>Hospital General de Requena</organization>
  </responsible_party>
  <keyword>Budesonide</keyword>
  <keyword>Formoterol</keyword>
  <keyword>Non cystic fibrosis bronchiectasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

